Updates at market open, adds further analyst comment in 4-5 bullets
** Shares in Novo Nordisk NOVOb.CO rise 3% after the Danish drugmaker posted a quarterly operating profit above estimates
** Novo books EBIT of 38.79 billion Danish crowns ($5.91 billion) for Q1, 4% above consensus expectations
** It now expects its sales in 2025 to grow 13%-21%, against the 16%-24% growth it saw in in February
** J.P.Morgan says the outlook cut was largely anticipated by the market
** Any weakness today is a buying opportunity ahead of the potential for improving Wegovy growth, JPM says
** Jefferies analysts say the outlook cut is likely around 1-2 pp more than expected
** Stock down around 29% YTD as of Tuesday's close
($1 = 6.5648 Danish crowns)
(Reporting by Boleslaw Lasocki)
((boleslaw.lasocki@thomsonreuters.com; +48 58 769 66 00;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。